Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Scarpa, Aldo ^a   Sikora, Katarzyna ^a   Fassan, Matteo ^a   Rachiglio, Anna Maria ^b   Cappellesso, Rocco ^c   Antonello, Davide ^a   Amato, Eliana ^a   Mafficini, Andrea ^a   Lambiase, Matilde ^b   Esposito, Claudia ^b   Bria, Emilio ^d   Simonato, Francesca ^c   Scardoni, Maria ^a   Turri, Giona ^a   Chilosi, Marco ^a   Tortora, Giampaolo ^d   Fassina, Ambrogio ^c   Normanno, Nicola ^e  

^a UNIVERSITY OF VERONA   (Italy)

^b Pharmacogenomic Laboratory   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRAF GENE; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPATHOLOGY; DNA DETERMINATION; DNA EXTRACTION; EGFR GENE; FEMALE; FGFR3 GENE; GENE; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC MARKER; HUMAN; HUMAN CELL; KRAS GENE; LUNG ADENOCARCINOMA; MALE; MAP2K1 GENE; MET GENE; MOLECULAR TYPING; MUTATIONAL ANALYSIS; PIK3CA GENE; PTEN GENE; SEX RATIO; SMAD4 GENE; STK11 GENE; TP53 GENE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; REPRODUCIBILITY OF RESULTS;

EID: 84893411121     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080478     Document Type: Article

References (45)

1. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359: 1367-1380.
2. Herbst RS, Lippman SM (2007) Molecular signatures of lung cancer-toward personalized therapy. N Engl J Med 356: 76-78. (Pubitemid 46041757)
3. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
4. Travis WD, World Health Organization, International Agency for Research on Cancer, International Association for the Study of Lung Cancer, International Academy of Pathology. (2004) Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press.
5. Fassina A, Cappellesso R, Simonato F, Lanza C, Marzari A, et al. (2012) Fine needle aspiration of non-small cell lung cancer: current state and future perspective. Cytopathology 23: 213-219.
6. Fassina A, Cappellesso R, Fassan M (2011) Classification of non-small cell lung carcinoma in transthoracic needle specimens using microRNA expression profiling. Chest 140: 1305-1311.
7. Rossi A, Pasquale R, Esposito C, Normanno N (2013) Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients? Cancer Treat Rev 39: 489-497.
8. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
9. Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, et al. (2010) Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 28: 744-752.
10. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, et al. (2012) Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18: 382-384.
11. Sun Y, Ren Y, Fang Z, Li C, Fang R, et al. (2010) Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 28: 4616-4620.
12. Janne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, et al. (2013) Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 14: 38-47.
13. De Luca A, Normanno N (2010) Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. Curr Drug Targets 11: 851-864.
14. Normanno N, Rachiglio AM, Roma C, Fenizia F, Esposito C, et al. (2013) Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. J Cell Biochem 114: 514-524.
15. Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, et al. (2012) Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 5: 1706-1713.
16. Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, et al. (2011) Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 29: 3316-3321.
17. Goto K, Satouchi M, Ishii G, Nishio K, Hagiwara K, et al. (2012) An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol 23: 2914-2919.
18. Geurts-Giele WR, Dirkx-van der Velden AW, Bartalits NM, Verhoog LC, Hanselaar WE, et al. (2013) Molecular diagnostics of a single multifocal non-small cell lung cancer case using targeted next generation sequencing. Virchows Arch 462: 249-254.
19. Gazziero A, Guzzardo V, Aldighieri E, Fassina A (2009) Morphological quality and nucleic acid preservation in cytopathology. J Clin Pathol 62: 429-434.
20. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, et al. (2012) A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6: 80-92.
21. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, et al. (2011) Integrative genomics viewer. Nat Biotechnol 29: 24-26.
22. Sorio C, Moore PS, Ennas MG, Tecchio C, Bonora A, et al. (2004) A novel cell line and xenograft model of ampulla of Vater adenocarcinoma. Virchows Arch 444: 269-277. (Pubitemid 38446440)
23. Marchetti A, Normanno N, Pinto C, Taddei GL, Adamo V, et al. (2010) Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica 102: 119-126.
24. Fassina A, Gazziero A, Zardo D, Corradin M, Aldighieri E, et al. (2009) Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis. J Clin Pathol 62: 1096-1102.
25. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, et al. (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16. (Pubitemid 43199589)
26. Sanchez-Cespedes M (2011) The role of LKB1 in lung cancer. Fam Cancer 10: 447-453.
27. Gao Y, Ge G, Ji H (2011) LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor. Protein Cell 2: 99-107.
28. Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, et al. (2010) Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS One 5: e14117.
29. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, et al. (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1: 78-89.
30. An SJ, Chen ZH, Su J, Zhang XC, Zhong WZ, et al. (2012) Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One 7: e40109.
31. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, et al. (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150: 1107-1120.
32. Ellis LM, Hicklin DJ (2009) Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology. Clin Cancer Res 15: 7471-7478.
33. Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, et al. (2010) The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A 107: 6459-6464.
34. Kawano O, Sasaki H, Endo K, Suzuki E, Haneda H, et al. (2006) PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 54: 209-215. (Pubitemid 44764916)
35. Cheng L, Alexander RE, Maclennan GT, Cummings OW, Montironi R, et al. (2012) Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol 25: 347-369.
36. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, et al. (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17.
37. Pao W, Hutchinson KE (2012) Chipping away at the lung cancer genome. Nat Med 18: 349-351.
38. Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12: 175-180.
39. Fassina A, Corradin M, Zardo D, Cappellesso R, Corbetti F, et al. (2011) Role and accuracy of rapid on-site evaluation of CT-guided fine needle aspiration cytology of lung nodules. Cytopathology 22: 306-312.
40. Kris MG, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. (2011) Identification of driver mutations in tumour specimens from 1000 patients with lung adenocarcinoma for the Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 29: Suppl, abstract CRA 7506.
41. Peled N, Palmer G, Hirsch FR, Wynes MW, Ilouze M, et al. (2012) Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 7: e14-16.
42. Daniels M, Goh F, Wright CM, Sriram KB, Relan V, et al. (2012) Whole genome sequencing for lung cancer. J Thorac Dis 4: 155-163.
43. Thomas A, Rajan A, Lopez-Chavez A, Wang Y, Giaccone G (2013) From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Ann Oncol 24: 577-585.
44. Buttitta F, Felicioni L, Del Grammastro M, Filice G, Di Lorito A, et al. (2013) Effective Assessment of Egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next Generation Sequencing. Clin Cancer Res 19: 691-698.
45. Chilosi M, Murer B (2010) Mixed adenocarcinomas of the lung: place in new proposals in classification, mandatory for target therapy. Arch Pathol Lab Med 134: 55-65.